Document is current
Any future updates will be listed below
-
Authors
Filion, Raphaël
St-Georges-Robillard, Amélie
Chaudoir, Henri
Ritch, Sabrina
Ndongo, Mamadou
Chua, Xue Ying
Laurent, Etienne
Mes-Masson, Anne-Marie
Ajji, Abdellah
Gervais, Thomas
-
Funding
Funding for this research was provided by:
Institut du Cancer de Montréal (Canderel Fellowship)
Institut du Cancer de Montréal (Canderel Fellowship)
Mitacs (Accelerate Program)
Mitacs (Accelerate Program)
Mitacs (Accelerate Program)
Canada First Research Excellence Fund (TransMedTech Institute)
Canada First Research Excellence Fund (TransMedTech Institute)
Canada First Research Excellence Fund (TransMedTech Institute)
Canada First Research Excellence Fund (TransMedTech Institute)
Canada First Research Excellence Fund (TransMedTech Institute)
Natural Sciences and Engineering Research Council of Canada (RGPIN2020-06838)
Natural Sciences and Engineering Research Council of Canada (RGPIN2020-06838)
Natural Sciences and Engineering Research Council of Canada (RGPIN2020-06838)
- License Information
-
More Information
Article History
Received: 23 May 2025
Accepted: 19 August 2025
First Online: 26 September 2025
Declarations
:
: E.L. is CEO of, member of the board for and has financial interest in 9397-2677 Québec Inc. (MISO Chip), a company focused on using 3D human tumor explant models to deliver functional, precision oncology solutions for drug development companies and patients. T.G. is member of the board for MISO Chip Inc. and has financial interest in the company. X.Y.C and M.N. are employees of DBM Technologies Inc. Other authors do not have competing interests.
: All procedures involving mice were performed according to the Guidelines for the Care and Use of Laboratory Animals of the CRCHUM, which are in accordance with the ARRIVE guidelines, and approved by the Animal Ethics Committee (# ANI-2425-03).
